It is reported that SBF2-AS1 is more highly expressed in IDH-wildtype than in IDH-mutant glioma and its knockdown in glioblastoma upregulates miR-338-3p, but downregulates EGF-like domain multiple 7 (EGFL7), thereby inhibiting angiogenesis (Cancer Genome Atlas Research Network et al. 2015; Yu et al. 2017; Zhang et al. 2021). The gene discussed is SBF2; the disease is central nervous system cancer.